{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:58:12Z","timestamp":1770512292575,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Interdisciplinary Intensive Care"},{"name":"Department of Pain Research and Treatment, Chair of Anesthesiology and Intensive Therapy, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Department of Palliative Medicine Poznan University of Medical Sciences, Poland"},{"name":"National Science Centre, Poland","award":["OPUS 11 2016\/21\/B\/NZ4\/00128"],"award-info":[{"award-number":["OPUS 11 2016\/21\/B\/NZ4\/00128"]}]},{"name":"Institute of Pharmacology Polish Academy of Sciences"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pharep.2018.01.005","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:41:10Z","timestamp":1517406070000},"page":"812-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tapentadol \u2013 A representative of a new class of MOR-NRI analgesics"],"prefix":"10.1007","volume":"70","author":[{"given":"Renata","family":"Zaj\u0105czkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Przew\u0142ocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kocot-K\u0119pska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Mika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Leppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Wordliczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"8","key":"10.1016\/j.pharep.2018.01.005_bib0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejpain.2010.05.005","article-title":"Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain","volume":"14","author":"Schroder","year":"2010","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.005_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/jpet.110.175042","article-title":"Synergistic interaction between the two mechanisms of action of tapentadol in analgesia","volume":"337","author":"Schroder","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2018.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharep.2018.01.005_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2018.01.005_bib0025","unstructured":"http:\/\/www.evaluategroup.com\/Universal\/View.aspx?type=Story&id=252954."},{"key":"10.1016\/j.pharep.2018.01.005_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","article-title":"Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally acting analgesics on the horizon","volume":"14","author":"Kress","year":"2010","journal-title":"Eur J Pain"},{"key":"10.1016\/j.pharep.2018.01.005_bib0035","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1358\/dof.2006.031.12.1047744","article-title":"Tapentadol hydrochloride","volume":"31","author":"Tzschentke","year":"2006","journal-title":"Drugs Fut"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.005_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2018.01.005_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neulet.2011.01.014","article-title":"The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (\u03bc-opioid receptor) knockout mice","volume":"491","author":"K\u00f6gel","year":"2011","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.005_bib0050","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1124\/jpet.113.207704","article-title":"Spinal-supraspinal and intrinsic \u03bc-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice","volume":"347","author":"Christoph","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2018.01.005_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2013.08.017","article-title":"Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain","volume":"562","author":"Meske","year":"2014","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.005_bib0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1213\/ANE.0000000000001669","article-title":"Effect of tapentadol on splenic cytokine production in mice","volume":"124","author":"Franchi","year":"2017","journal-title":"Anesth Analg"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2018.01.005_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2011.05.029","article-title":"Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain","volume":"666","author":"Christoph","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2018.01.005_bib0070","author":"Janssen Pharmaceuticals Inc"},{"key":"10.1016\/j.pharep.2018.01.005_bib0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/187231208783478434","article-title":"Investigations into the drug\u2013drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes","volume":"2","author":"Kneip","year":"2008","journal-title":"Drug Metab Lett"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.005_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1592\/phco.30.1.25","article-title":"Effects of acetaminophen, naproxen and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug\u2013drug interaction studies","volume":"30","author":"Smit","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2018.01.005_bib0085","first-page":"55","article-title":"The pharmacokinetics of tapentadol are not affected by omeprazole: results of a 2-way crossover drug-interaction study in healthy subjects","volume":"7","author":"Mangold","year":"2007","journal-title":"Pain Pract"},{"key":"10.1016\/j.pharep.2018.01.005_bib0090","first-page":"1104","article-title":"Effects of metoclopramide on tapentadol pharmacokinetics: results of an open-label, cross-over, drug\u2013drug interaction study","volume":"49","author":"Smit","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharep.2018.01.005_bib0095","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.clinthera.2009.12.003","article-title":"Tapentadol hydrochloride: a centrally acting oral analgesic","volume":"31","author":"Wade","year":"2009","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.005_bib0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5055\/jom.2015.0289","article-title":"Tolerability and efficacy of tapentadol extended release in elderly patients\u226575 years of age with chronic osteoarthritis knee or low back pain","volume":"11","author":"Biondi","year":"2015","journal-title":"J Opioid Manag"},{"issue":"8","key":"10.1016\/j.pharep.2018.01.005_bib0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1049909111434634","article-title":"Pharmacology update tapentadol for neuropathic pain","volume":"29","author":"Pierce","year":"2012","journal-title":"Am J Hosp Palliat Med"},{"key":"10.1016\/j.pharep.2018.01.005_bib0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12325-013-0015-6","article-title":"Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase IIIb study","volume":"30","author":"G\u00e1lvez","year":"2013","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.005_bib0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clinthera.2014.07.005","article-title":"Practical consideration for the use of tapentadol prolonged release for the management of severe chronic pain","volume":"37","author":"S\u00e1nchez Del \u00c1guila","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharep.2018.01.005_bib0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejphar.2014.11.032","article-title":"The influence of \u03bc-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy","volume":"749","author":"Gon\u00e7alves","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharep.2018.01.005_bib0125","doi-asserted-by":"crossref","first-page":"e102027","DOI":"10.1371\/journal.pone.0102027","article-title":"Spinal cord transection-induced allodynia in rats\u2013behavioral, physiopathological and pharmacological characterization","volume":"9","author":"M'Dahoma","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharep.2018.01.005_bib0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.111.181263","article-title":"Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain","volume":"339","author":"Schiene","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.005_bib0135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1254\/jphs.14081FP","article-title":"Effect of the norepinephrine transporter (NET) inhibition on \u03bc-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model","volume":"125","author":"Ono","year":"2014","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.pharep.2018.01.005_bib0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ejp.530","article-title":"Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach","volume":"19","author":"Falk","year":"2015","journal-title":"Eur J Pain"},{"key":"10.1016\/j.pharep.2018.01.005_bib0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.pharep.2018.01.005_bib0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.005_bib0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","article-title":"Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","volume":"10","author":"Wild","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.pharep.2018.01.005_bib0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JPR.S30540","article-title":"Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study","volume":"5","author":"Steigerwald","year":"2012","journal-title":"J Pain Res"},{"key":"10.1016\/j.pharep.2018.01.005_bib0165","article-title":"Tapentadol for chronic musculoskeletal pain in adults","volume":"5","author":"Santos","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharep.2018.01.005_bib0170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40261-013-0102-0","article-title":"Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain","volume":"33","author":"Steigerwald","year":"2013","journal-title":"Clin Drug Invest"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.005_bib0175","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/papr.12361","article-title":"Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with Oxycodone\/Naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 trial","volume":"16","author":"Baron","year":"2016","journal-title":"Pain Pract"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.005_bib0180","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/papr.12308","article-title":"Effectiveness of tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 study","volume":"16","author":"Baron","year":"2016","journal-title":"Pain Pract"},{"issue":"9","key":"10.1016\/j.pharep.2018.01.005_bib0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/JPR.S112418","article-title":"Efficacy and tolerability balance of oxycodone\/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations","volume":"11","author":"Ueberall","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.pharep.2018.01.005_bib0190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/JPR.S129056","article-title":"Tapentadol extended release for the management of chroni\u0107 neck pain","volume":"10","author":"Billeci","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.pharep.2018.01.005_bib0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.36076\/ppj.2014\/17\/329","article-title":"Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain","volume":"17","author":"Kress","year":"2014","journal-title":"Pain Physician"},{"issue":"11","key":"10.1016\/j.pharep.2018.01.005_bib0200","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1185\/03007995.2012.739151","article-title":"Tapentadol in cancer pain management: a prospective, open-label study","volume":"28","author":"Mercadante","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.pharep.2018.01.005_bib0205","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/03007995.2013.831816","article-title":"Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain","volume":"29","author":"Imanaka","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.pharep.2018.01.005_bib0210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1871525714666160405110833","article-title":"Tapentadol PR for pain syndromes in real life patients with hematological malignancy","volume":"14","author":"Brunetti","year":"2016","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.pharep.2018.01.005_bib0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/JPR.S83490","article-title":"Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease","volume":"8","author":"Coluzzi","year":"2015","journal-title":"J Pain Res"},{"key":"10.1016\/j.pharep.2018.01.005_bib0220","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1007\/s00520-016-3369-x","article-title":"Effectiveness of tapentadol prolonged release for the managementof painful mucositis in head and neck cancers during intensity modulated radiation therapy","volume":"24","author":"Mazzola","year":"2016","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.pharep.2018.01.005_bib0225","first-page":"1","article-title":"Tapentadol for the management of neuropathic pain from oxaliplatin chemotherapy","volume":"2","author":"Borja","year":"2014","journal-title":"Am J Int Med"},{"issue":"September (9)","key":"10.1016\/j.pharep.2018.01.005_bib0230","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011460","article-title":"Oral tapentadol for cancer pain","author":"Wiffen","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.pharep.2018.01.005_bib0235","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1185\/03007995.2011.611494","article-title":"Systematic review of tapentadol in chronic severe pain","volume":"27","author":"Riemsma","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"Suppl. 4","key":"10.1016\/j.pharep.2018.01.005_bib0240","doi-asserted-by":"crossref","first-page":"P55","DOI":"10.1016\/j.jpain.2011.02.225","article-title":"A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies","volume":"12","author":"Biondi","year":"2011","journal-title":"J Pain"},{"issue":"10","key":"10.1016\/j.pharep.2018.01.005_bib0245","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5414\/CPP48678","article-title":"A thorough Qt\/QTc study of multiple doses of tapentadol immediate release in healthy subjects","volume":"48","author":"Oh","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2018.01.005_bib0250","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40261-014-0209-y","article-title":"Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis","volume":"34","author":"Biondi","year":"2014","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.005_bib0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5055\/jom.2015.0270","article-title":"Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency","volume":"11","author":"Eichenbaum","year":"2015","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.pharep.2018.01.005_bib0260","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/TCRM.S79409","article-title":"The unsolved case of bone-impairing analgesics: the endocrine effects of opioids on bone metabolism","volume":"11","author":"Coluzzi","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.pharep.2018.01.005_bib0265","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2009.45.7.1395291","article-title":"Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanism of action in a single molecule","volume":"45","author":"Tzschenke","year":"2009","journal-title":"Drugs Today"},{"issue":"5","key":"10.1016\/j.pharep.2018.01.005_bib0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/11589080-000000000-00000","article-title":"Tapentadol in pain management","volume":"25","author":"Hartrick","year":"2011","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pharep.2018.01.005_bib0275","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1533-2500.2011.00487.x","article-title":"Current considerations for the treatment of severe chronic pain: the potential for tapentadol","volume":"12","author":"Pergolizzi","year":"2012","journal-title":"Pain Pract"},{"issue":"3","key":"10.1016\/j.pharep.2018.01.005_bib0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11208600-000000000-00000","article-title":"Tapentadol extended release in adults with chronic pain","volume":"72","author":"Hoy","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2018.01.005_bib0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.36076\/ppj.2013\/16\/27","article-title":"Efficacy of tapentadol ER for managing moderate to severe chronic pain","volume":"16","author":"Afilalo","year":"2013","journal-title":"Pain Physician"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017306138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114017306138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:30Z","timestamp":1752611850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2018.01.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1734114017306138"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.005","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapentadol \u2013 A representative of a new class of MOR-NRI analgesics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2018.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}